Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo targets Hard-to-Treat childhood cancers

NCT ID NCT06607692

Recruiting now Disease control Sponsor: Fundación de investigación HM Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 25 participants will receive the treatment every 8 weeks for up to four cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

177Lu-DOTATATE (Lutathera) and olaparib

What this could lead to

If successful, this combination could offer a new treatment option for children with certain hard-to-treat cancers that have come back after standard therapy.

What could go wrong

This is an early-phase trial with only 25 participants, so the benefits are uncertain. The combination may cause significant side effects, and it is not yet known if it will shrink tumors or improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex neoplasm adrenal gland cancer adrenal gland neoplasm cancer diffuse intrinsic pontine glioma ependymoma esthesioneuroblastoma Esthesioneuroblastoma, Olfactory glioblastoma glioma malignant glioma medulloblastoma meningioma neuroblastoma neuroendocrine neoplasm osteosarcoma paraganglioma pheochromocytoma pheochromocytoma-paraganglioma Recurrence refractory malignant neoplasm synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL TUMOURS CARCINOMA ADRENAL DIPG EPENDYMOMA EPENDYMOMA RECURRENT ESTHESIONEUROBLASTOMA GLIOBLASTOMA GLIOBLASTOMA (GBM) HIGH GRADE GLIOMAS HIGH-RISK NEUROBLASTOMA MEDULLOBLASTOMA MEDULLOBLASTOMA RECURRENT MENINGIOMA NEUROBLASTOMA RECURRENT NEUROENDOCRINE TUMOURS (NET) OSTEOSARCOMA RECURRENT PARAGANGLIOMA PARAGANGLIOMA/ PHAEOCHROMOCYTOMA PHEOCHROMOCYTOMA SOLID TUMOR CANCER SOLID TUMOR REFRACTORY TO CONVENTIONAL TREATMENT SYNOVIAL SARCOMAS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • HM Monteprincipe

    RECRUITING

    Boadilla del Monte, Madrid, 28660, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••